Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025.
Antranik Tavitian | Reuters
Eli Lilly said on Tuesday it would buy Centessa Pharmaceuticals in a deal valued at about $6.3 billion to expand into treatments for sleep-wake disorders.
The U.S. drugmaker has offered Frankfurt-listed Centessa $38 per share in cash. Centessa’s U.S.-listed shares jumped 46% in premarket trading.
Lilly has also offered one non-transferrable contingent value right (CVR) of about $9, taking the total deal value to up to $7.8 billion.
About The Author
